Wild type RAS plays critical roles in both RAS mutant and RAS wild type cancers, in a context-dependent manner. The wild type KRAS isoform largely acts as a tumour suppressor in the …

Different methods can be used to detect RAS mutations in colorectal cancer specimens, such as mutation-specific real-time polymerase chain reaction (R T-PCR), Sanger sequencing, …

The disappearance of RAS clones in the plasma of patients diagnosed with RAS mutations is known as “neo-RAS wild type (wt)” or “RAS conversion”. Current scientific evidence regarding …

New randomized head-to-head trials have shown a possible survival advantage with the preferential choice of targeted anti-epidermal growth factor receptor (anti-EGFR) over anti …

2023年7月24日 · Patients treated with anti-epidermal growth factor receptor (anti-EGFR) will ultimately develop acquired resistance promoted by clonal selection, mainly the emergence of …

Our study indicates that FOLFOX + panitumumab has the major probability to provide an improvement of survival with a good safety profile in patients with RAS WT mCRC with an …

2023年3月15日 · In the RAS wild-type population, the current standard of care involves chemotherapy combined with anti-EGFR agents as first-line treatment, followed by a second …

2023年1月24日 · Background: Metastatic colorectal cancers (mCRC) with wild-type KRAS are often sensitive to anti-EGFR, but occasionally develop resistance within treatment. A major …

Upfront KRAS and NRAS gene testing ('RAS') is the standard of care for metastatic colorectal cancer (mCRC), to guide first-line treatment. The presence of RAS mutation (MT) is a negative …

2021年4月28日 · RAS -mutated tumors were originally thought to proliferate independently of upstream signaling inputs, but we now know that non-mutated wild-type (WT) RAS proteins …